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Abstract 
Methods- In this preliminary, non-randomized study, patients with stage III and IVA 
oropharyngeal carcinoma treated with transoral laser microsurgery (TLM) were assessed pre-
treatment and three months following treatment using the MD Anderson Dysphagia Inventory 
(MDADI), the Performance Status Scale (PSS) and a timed water swallow test (WST).  Comparisons 
were made with an historical CRT cohort.  
Results- Based on patients with measurements at both times, the decrease in score 
between baseline and 3 months was greater for CRT patients (n=26-28) than for TLM (n=20-21) 
patients for each of MDADI, PSS and WST.  A repeated measures analysis that looked at all three 
scores simultaneously and allowed for missing values gave mostly similar results (except for 
MDADI). 
Conclusions- TLM was associated with good early swallowing outcomes at 3 months and may 
offer a benefit over CRT.  The results should be viewed as preliminary data, providing useful 
reference for any proposed controlled trial. 
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 Introduction 
The management of oropharyngeal squamous cell carcinoma (OPSCC) is a hotly debated topic. The 
increased survival noted with concurrent chemoradiotherapy (CRT), over radiotherapy alone, along 
with the recognition that traditional open surgical approaches were associated with greater 
morbidity
1
 led to an ever increasing trend towards primary non-surgical treatment for these 
patients.  However, the realisation that CRT is associated with greater long term morbidity then 
radiotherapy alone, the popularisation of Transoral Laser Microsurgery (TLM) and Transoral Robotic 
Surgery (TORS) and the recognition of a distinct population of patients with OPSCC cause by Human 
Papilloma Virus (HPV), has rekindled the debate. The incidence of HPV positive OPSCC now 
outweighs that of HPV negative disease in some areas of the world.  The prognosis from HPV 
positive OPSCC is better than HPV negative disease and the survival following treatment appears 
roughly similar when taken from distinct non-surgical and surgical trials
2, 3
.   
With the improved prognosis for HPV positive OPSCC patients has come the question of 
survivorship.  These patients tend to be younger, generally medically fitter, non-smokers and work. 
Swallowing is a top priority concern for head and neck cancer survivors
4
. Furthermore, younger 
patients report more severe swallowing difficulties than older patients
4
.   Whilst the issue of post-
treatment function is clearly of huge importance, the literature does not allow a straightforward 
assessment of the outcomes following different treatment options. 
How can we maximise functional outcome whilst maintaining survival prognosis?  Advocates of TLM 
and TORS claim that swallowing is improved with these methods; patients with low volume disease 
(T1 and T2), N0 or N1 neck disease, clear surgical margins and no extracapsular spread are 
candidates for single modality surgery.  However, this group of patients forms roughly 25% of OPSCC 
patients and would be candidates for radiotherapy alone rather than CRT.  Surgery allows accurate 
staging of the disease, enabling reduced doses of adjuvant radiotherapy, with or without 
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chemotherapy, and potential reduction in the radiotherapy fields, particularly for lateralised OPSCC 
tumours.  Advocates of CRT cite the greater level of evidence in support of its survival efficacy and 
the potential benefits of Intensity Modulated Radiotherapy (IMRT), although there is no published 
research directly comparing swallowing outcomes for IMRT and conventional (C)RT. In mixed 
treatment groups, larger radiation fields, accelerated fractionation and the addition of 
chemotherapy were associated with worse swallowing
5-7
.   
Following a number of patients who suffered particularly severe functional morbidity following 
primary CRT, with negligible improvement in the first year following treatment
8
, this unit opted to 
move to offer primary TLM for patients with OPSCC.  The initial aim of this study was to analyse 
swallowing outcomes in both TLM and CRT groups.  However, analysis revealed that very few 
patients with surgically appropriate disease received CRT and over the period in question primary 
CRT was mainly given to T4 tumours.  Early swallowing function following TLM has therefore been 
compared with an historic cohort of stage-matched patients undergoing non-surgical treatment and 
who received the same prospective swallowing evaluation.   
The primary aim of this preliminary, non-randomized study was to assess the change in early 
swallowing function from baseline to 3 months following treatment between the TLM and historical 
CRT groups.  Specifically, patients with stage III and IVA 
9
 disease have been included.  These stages 
represent tumours that merit treatment with chemoradiotherapy and are resectable via TLM 
surgery.  Previous work indicates that while some improvement in swallowing does occur after 3 
months the improvement is small.  Longitudinal studies have shown that swallowing at 3 months is 
a very strong indicator of likely longer term function
5, 6, 8
 . 
Materials and Methods 
Patients presenting to the Sunderland Royal Hospital head and neck multidisciplinary team meeting 
with primary resectable stage III and IVA squamous cell carcinoma of the oropharynx from August 
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2011 until March 2013 were treated with TLM surgery and adjuvant therapy.  This was not a trial of 
the technique, but more a change in policy by the team away from CRT.  All patients undergoing 
TLM were included in a prospectively collected database.  Swallowing is a multi-dimensional 
construct, and assessments from different domains can give differing results. Therefore, three 
outcomes were collected: a swallowing questionnaire, a clinician-rated dietary texture scale and a 
timed water swallow test, as detailed below.  Data were collected at baseline, which will have 
occurred shortly after diagnostic biopsies, and at 3 months following completion of all therapy.  
Functional outcomes were then compared against a historical non-surgical case series recruited for a 
previous study
8
.  All patients with stage III and IVA disease of the oropharynx were extracted from 
this research database.  These included some patients receiving radiotherapy alone, for various 
reasons.  Routine HPV testing was only performed for the TLM group, comprising  p16 
immunohistochemistry and when this was positive, in-situ hybridisation for high risk HPV
10
. 
 
Treatment - TLM 
Surgical resection of the primary tumour was performed as previously described in the literature 
11
.  
The FK retractor (Olympus UK) was used for access and under microscopic visualisation the tumour 
was resected using the CO2 Laser aiming for a macroscopic surgical margin of 1cm.  In most 
instances, resection proceeded as recommended by Steiner and Ambrosch
12
; transecting the tumour 
mass to assess depth.  Following what was deemed adequate resection, separate marginal 
specimens were resected to aid in confirmation of complete clearance.  Specimens were pinned on 
corkboards and orientated with diagrams.  Routine frozen sections were not used.  Ipsilateral 
selective neck dissections were performed for lateralised tumours and bilateral selective neck 
dissections performed for midline disease.  Initially, neck dissection was performed 2 weeks after 
TLM to the primary site as described.  However, following a mortality due to haemorrhage 5 days 
post-operatively, following hospital discharge and presumed to arise from the resection site, this 
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practice was altered.  Neck dissection is now performed simultaneously to resection of the primary 
site, to allow ligation of the feeding external carotid artery branches in an attempt to reduce this 
risk. 
Post-operative radiotherapy was administered at a dose of 60-65Gy for two or more pathologically 
involved neck nodes and post-operative concurrent CRT (weekly cisplatin at 30-40mg/m
2
) was 
initiated in patients with pathologically involved primary site margins or extra-capsular spread within 
the resected lymph nodes.  
 
Treatment – CRT cohort 
The radiotherapy regime was 63Gy in 30 fractions over six weeks using 3D conformal techniques. 
This was combined with either Cisplatin 40mg/m2 in six cycles or Mitomycin C 15mg/m2 in two 
cycles. Patients were recruited from two North-East of England hospitals and treated at a single 
centre between 2006 and 2008. 
 
Functional Outcomes 
Patient rated swallowing outcomes were collected at baseline prior to treatment and at three 
months post treatment completion (including adjuvant therapy in the surgery group) using the MD 
Anderson Dysphagia Inventory (MDADI). This self-report questionnaire has proven reliability and 
validity, and is sensitive to changes over time 4, 8, 13. It has twenty items each with a five point 
response scale and can be summarised using a total score (range 20-100). A score of ≥80 indicates 
minimal or no swallowing problems. 
Dietary texture restrictions were clinician rated using the Normalcy of Diet scale, which is a single 
item sub-section of the Performance Status Scales (PSS) and can be marked independently. The PSS 
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has good reliability and validity as well as sensitivity to differences in performance and change 
over time8, 14. The scale has ten ranked categories ranging from 0 (nil by mouth) to 100 (full diet 
without restrictions). 
Swallow performance was assessed using the timed 100mL Water Swallow Test (WST)
15
. Patients 
were instructed to swallow 100mLs of liquid "as quickly as is comfortably possible" and from this, a 
measure of swallow capacity (mls per second) was calculated, with a lower score indicating a 
poorer outcome. The test was not performed if the patient reported choking on fluids and was 
scored as a zero. The test has good reliability and validity and is sensitive to measuring change 
over time and differentiating between treatment outcomes8, 16, 17 
 
Statistical Analysis 
Both parametric (repeated measures) and non-parametric analyses were performed to compare the 
change in swallowing scores between baseline and 3 month follow up between the two groups (TLM 
and CRT).  The multivariate repeated measures analysis, conducted using the GLM Repeated 
Measures option in SPSS, looked at changes in all three scores simultaneously and adjusted for 
missing values via multiple imputation, allowing for the fact that all scores lie between 0 and 100.  
This analysis was based on the assumption that the scores are normally distributed. However, due 
to the construction of the MDADI and PSS questionnaires, the assumption of normality is 
questionable; for instance, a difference of 10 on the MDADI score between 90 and 80 may not 
compare to the clinical difference of 10 between 50 and 40 on the same scale.  Furthermore, as 
highlighted below, the scores have skewed distributions.  Consequently, when considering each 
score in turn, Mann-Whitney U-tests were used to look for differences in the change in score 
between groups, based on those patients with measurements at both baseline and 3 months.  
Particular attention was given to p-values less than 0.05.   Analyses were performed using SPSS 
version 19. 
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 Ethical Considerations 
Formal local research ethics committee approval was obtained for the original chemoradiotherapy 
group.  Subsequently the collection of the three swallowing outcomes has become routine practice 
in this department.  Approval was obtained from the Sunderland Royal Hospital clinical governance 
department to collect the data. 
 
Results 
Twenty-three patients treated with TLM and thirty-three patients treated with primary non-surgical 
management, with complete demographic and tumour staging data, were included in the analysis.  
Every consecutive patient undergoing TLM within the study timeframe has been included in the 
descriptive results.  Ninety-four percent of patients in the historical non-surgical cohort agreed to 
take part in the data collection.  Twenty-nine of the non-surgical group were treated with 
concurrent chemoradiotherapy.  All 33 will be referred to as the CRT group.  The characteristics of 
each group are summarised in table 1.  Unfortunately, at the time that data were collected for the 
historic CRT cohort, nodal status was classified as N2 disease and was not sub classified further.   
Nineteen patients in the TLM group had tumours deemed to be HPV positive. 
Adjuvant therapy was given to 21 of the TLM patients; 17 receiving radiotherapy alone and 4 
receiving chemoradiotherapy.  One of these four patients had adjuvant chemoradiotherapy for 
positive margins the other three for nodal extracapsular spread (ECS).  Two patients refused the 
addition of chemotherapy for ECS. 
Some missing data occurred in 4 of the TLM group; as detailed above, one patient died of a post-
operative haemorrhage, one failed to attend for follow-up and failed to complete all questionnaires, 
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and the absence of two PSS Normalcy of diet scores was an accidental scoring omission.  Seven 
patients in the CRT had missing data due to post-treatment mortality (n=1), persistent disease 
preventing collection of data (n=2), mental health concerns (n=1) and three failed to attend follow-
up or return postal questionnaires (n=3).  The numbers of patients with complete data for each 
swallowing outcome are detailed in table 2 and vary from 20 to 21 for the TLM group and 26 and 
28 for the CRT group. 
The mean and standard deviations for pre- and 3-month post treatment swallowing scores are 
summarised in table 2, separately for the TLM and CRT groups.  Only patients with both pre- and 3-
month scores have been included here. Based on a Mann-Whitney U-test for patients with both pre- 
and 3-month scores, there was no significant difference in baseline scores between the two groups 
for MDADI scores (p=0.078), PSS Normalcy of diet (p=0.51) nor WST (p=0.55).  However, when all 
patients (including those with missing data) were included in this calculation, there was a significant 
difference in baseline scores on the MDADI between the two groups (p=0.012), but less evidence of 
a difference for PSS Normalcy of diet (p=0.082) and no evidence of a difference for WST (p=0.43).   
There were a higher proportion of T3 primary tumours in the CRT group (13/33) than the TLM 
group (5/23).  When T3 tumours were removed from the descriptive analysis, the CRT group had 
mean pre- and 3-month scores of 79.1 and 59.1 (MDADI), 76.4 and 36.0 (PSS Normalcy of diet) and 
17.3 and 13.0 (WST).  Relative to the entire CRT group, mean scores for T1-2 tumours were slightly 
lower in the case of MDADI and PSS Normalcy of diet and slightly higher in the case of WST. 
Based on MDADI, seventy six per cent of the TLM group (16/21) and ninety-two percent of the CRT 
group (24/26) reported more swallowing problems following treatment, compared with their 
baseline score. Using a complete case analysis,  the change in MDADI score between baseline and 3 
months was greater for CRT than for TLM (p=0.029, Mann-Whitney U), indicating a poorer patient 
reported swallowing outcome for the CRT group.  There was also evidence for a difference between 
the groups in the change in score for PSS Normalcy of diet (p<0.001, based on 9 out of 20 TLM and 
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25 out of 28 CRT patients with lower PSS Normalcy of diet scores at 3 months than at baseline) and 
WST (p=0.034, based on 10 out of 21 TLM and 20 out of 28 patients with lower WST scores at 3 
months than at baseline).  The mean values of the scores at baseline and 3 months for TLM and CRT 
patients are depicted in figures 1-3 and again are limited to those patients with both pre- and 3-
month data.  In particular, figures 2 and 3 show that for PSS Normalcy of diet and WST in particular, 
the change in score between baseline and 3 months is more marked for the CRT patients than for 
the TLM patients, suggesting that the former group had a poorer swallowing outcome. 
The mean (standard error, effect size[mean difference / standard deviation]) of the difference 
between the pre- and post-treatment measurements, based on those patients with both 
measurements, were:  11.7 (3.8, 0.66) and 22.3 (3.3, 1.31) for the MDADI scores in the TLM (n=21) 
and CRT (n=26)  groups respectively, 8.5 (4.4, 0.44) and 47.1 (5.3, 1.69) for the PSS Normalcy of diet 
in the TLM (n=20)  and CRT (n=28)  groups respectively, -0.1 (1.2, -0.018) and 5.3 (1.5, 0.68) for the 
WST in the TLM (n=21)  and CRT (n=28)  groups respectively. 
The multivariate repeated measures analysis based on all of the patients (assuming a normal 
distribution for the scores and using multiple imputation for the missing scores) found evidence for 
a difference between TLM and CRT in the change in score for PSS Normalcy of diet (p<0.001) and 
WST (p=0.03), but not for the MDADI (p=0.20)   
Five patients in the CRT group were unable to complete the WST due to high risk of gross aspiration 
at three months and scored zero.  No patients in the TLM group and none in either group at baseline 
scored zero. 
 
Discussion 
This is the first study to assess swallowing function after primary TLM for OPSCC using 3 different 
swallowing measures and to compare these with a matched group of CRT patients.  It follows the 
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methodology used by Patterson et al
8
 in analysing the swallowing outcomes with CRT for all head 
and neck cancer sites; the OPSCC cohort from this has formed the stage matched comparison group 
for this study.  The results of our preliminary, non-randomized study suggest that patients treated 
by TLM had significantly better swallowing self-report outcomes, diet texture scores and swallow 
performance outcomes at three months following treatment than the matched CRT group.  The 
differences in the results presented here may be attributable to decreased diffuse post-radiotherapy 
scarring. Fibrosis of the musculature reduces the efficiency, co-ordination and safety of the 
swallowing mechanism. It is a long-term condition, which can spread to surrounding tissues thus 
progressively reducing function.  Although the current study reports early post-treatment outcomes, 
patients appear to be functioning at a relatively high level and maintaining muscular condition, 
which may reduce the likelihood of chronic dysphagia.  
When assessing swallowing function it is important to realise that there is no single method of 
measuring outcomes.  Patients’ experiences do not always correlate with objective measures
18
.  
Therefore, both patient reported and clinician rated assessments were collected. These measures 
are routinely collected in our centre. The current study did not include any swallowing 
instrumentation, as this was rarely indicated from clinical assessment.  No one in the TLM was 
unable to complete the WST, whereas in the CRT group five patients could not complete the WST 
due to overt aspiration.   
These data make a valuable contribution to the evidence base on swallowing function following 
OPSCC.  Comparing surgical and non-surgical therapy in the setting of a controlled trial is 
challenging.  It was encouraging to read that the concept of a phase III RCT comparing transoral 
surgery with conventional CRT for OPSCC was discussed at a United States national cancer meeting 
in 2011
19
.  Given that survival outcomes appear approximately similar, functional outcome is likely to 
be a primary outcome for such a trial.  We believe that the combination of the MDADI, PSS 
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Normalcy of diet and WST offer a straightforward and reproducible method of capturing patient 
reported function and objective assessment in the clinical setting. 
This study has deficiencies and the two groups may not be directly comparable.  However, the 
results offer useful preliminary data for any RCT proposal.  There appears to be a benefit in 
swallowing as measured by the PSS and WST with TLM and adjuvant therapy over historical CRT.  
The benefits as measured by the MDADI are less clear but there does appear to be a modest benefit 
with TLM.  Not all patients in each group completed all 3 swallowing measures at the 2 time points.  
If a patient missed a test either pre-treatment or at follow up, this could not subsequently be 
rectified. Using multiple imputation to allow for missing data gave broadly similar results, but 
relied on an assumption of normality in the scores that is questionable.  
The baseline difference between the two groups was significant for the MDADI, when all patients 
including those with missing data were analysed.  The statistical methods used to analyse the results 
take into account baseline differences, but as mentioned earlier the MDADI is unlikely to be a 
uniform scoring system.  A difference of 10, whilst deemed a clinically significant difference, may not 
be equivalent from a start point of 89 compared to 81.  Why this baseline difference exists in this 
current study is interesting.  Options include: 
1. Small sample sizes and chance.  The baseline MDADI scores for TORS and CRT in the recent 
study by More et al 
20
 are equivalent and are more in line with the historic CRT cohort from this 
study. 
2. Between 2006 and 2008, when the CRT patients were treated, TLM was not routinely 
offered in this centre.  This may have led to more extensive diagnostic biopsies.  Now, a biopsy that 
does not breach the tumour margins is recommended with TLM in mind.  As baseline swallowing 
measurements were usually taken about 2 weeks after biopsy there may have been the potential for 
the biopsy sites to be more painful in the CRT group thus lowering swallowing scores. 
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3. There has been a rapid rise in HPV positive disease.  It is possible that a greater proportion 
of TLM patients were HPV positive than the CRT group.  HPV positive tumours are perhaps more 
discrete tumours, homogenous and unlikely to be present in surrounding epithelial field change, 
which may mean they cause less swallowing impairment. 
4. There was a higher proportion of advanced T-stage disease (T3) included in the historical 
CRT group (13/33) compared to the TLM group (5/23).  This could have led to a worse swallowing 
performance in the CRT group at baseline.  However our results do not support this suggestion for 
the MDADI or PSS. 
5. We must acknowledge the lack of N2 nodal sub classification in the CRT group.  No patients 
with N2c disease were treated in the TLM group.  It is difficult to conclude what effect the inclusion 
of patients with N2c disease in the CRT cohort would have had on the mean swallowing scores, 
other than to assume it would have worsened function.  Clearly N2c disease would have been 
treated with full dose radiotherapy to both sides of the neck. 
We do acknowledge a lack of comparative basic data between the two groups, eg. smoking status, 
alcohol consumption, co-morbidities.  We also recognise that a follow-up period of three months 
may be considered short.  However, as mentioned earlier, swallowing at 3 months is a strong 
indicator of future performance.  This study was intended to offer preliminary data.  No clinically 
significant difference was established with a view to performing a sample size calculation in 
advance.  However, for the purposes of an RCT, we would consider a difference of 10 on the 
MDADI to be a clinically significant difference. 
Irrespective of whether the 2 groups are directly comparable, it seems apparent that patients 
treated pragmatically with TLM +/- adjuvant therapy function well with respect to swallowing at 3 
months post-treatment.  If a score of 80 or more on the MDADI is considered to represent minimal 
or no swallowing problems, [4] then a mean score of 78 at 3 months for a group of stage III and IVA 
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OPSCC should be viewed positively.  Likewise the lack of any reduction in the objective WST in this 
group is impressive.  We accept that 2 out of 23 patients were treated with surgery alone and that 
only 4 had adjuvant chemoradiotherapy, but this is a pragmatic study and does represent the 
potential advantages of surgically staging the disease.  This study is too small to make any 
meaningful conclusions on how surgery alone compares to TLM + RT and how this compares to TLM 
+ CRT.  These are questions that need addressing in the setting of an RCT and we hope that these 
data add to the planning of any such trial. 
Attempting to form a conclusion on swallowing outcomes following OPSCC treatment from the 
current evidence is challenging.  Studies examining swallowing outcomes tend to be single 
institution series, small in number, lacking in homogenous data collection time points and employing 
a variety of swallowing measures have been used.  One of the clear criticisms of this study is that we 
have compared TLM versus conventional radiotherapy techniques and not IMRT.  More et al
20
 
recently looked at the MDADI scores for 20 patients undergoing TORS + adjuvant therapy and 20 
patients undergoing IMRT CRT for stage III and  IVA OPSCC.  Both groups had a baseline MDADI 
score of 78, in line with this study’s CRT group.  Swallowing was assessed at 3, 6 and 12 months, but 
for the TORS group the 3 month score coincided with adjuvant therapy whereas in our study we 
looked at 3 months following completion of all therapy.  Our study’s 3 month TLM results should 
therefore be viewed to be as equivalent time points to the 6 month scores in the study by More et 
al.  Whereas the TORS group improved from an MDADI score of 62 at 3 months to 76 and 78 at 6 
and 12 months respectively, the CRT group MDADI scores were 56 and 57 at 3 and 6 months, rising 
to 60 at 12 months.  The MDADI scores at 6 and 12 months statistically favoured the TORS group.  It 
is therefore evident that the conventional RT techniques used in our study led to very similar results 
to those of IMRT (59 and 56 respectively).  However, at a recent meeting, Roe et al
21
 did present 
slightly more encouraging results with IMRT techniques for primary CRT for OPSCC; among 62 
patients of all stages and all head and neck sites (but as with most series, predominantly stage III and 
IV OPSCC), the MDADI score rose to approximately 70 at 12 months post treatment. 
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 Conclusions  
This study should be regarded as providing preliminary data.  It suggests a benefit in swallowing self-
report outcomes, diet texture scores and swallow performance outcomes at three months following 
treatment with TLM +/- adjuvant therapy compared to the non-randomized historical CRT group. 
This adds to emerging evidence that primary transoral surgery offers a benefit in swallowing 
function over primary CRT.  However, only a sufficiently powered RCT will truly answer this question.  
This study may help provide the template for swallowing assessment and data to aid in planning of 
such a trial. 
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 Table 1. Patient demographics 
Demographic TLM (number =23) CRT  (number =33) 
Mean Age (SD) 59.3 (8.6) 59.3 (8.6) 
Gender: Male 
               Female 
17  
6 
26   
7 
Site of Tumour 
Tonsil 
Base of Tongue 
Posterior Pharyngeal Wall 
Soft Palate 
 
15 
7 
1 
0 
 
18 
11 
2 
2 
Overall Stage 
III 
IVA 
 
5 
18 
 
13 
20 
T Classification 
T1 
 
 
 
 
T2 
 
 
 
 
 
T3 
N Classification 
 
N2 
N2a 
N2b 
 
 
N1 
N2 
N2a 
N2b 
 
 
N0 
N1 
N2 
N2a 
N2b 
 
(n=5) 
 
1 
4 
(n=13) 
 
2 
 
2 
9 
 
(n=5) 
2 
1 
 
1 
1 
 
(n=5) 
5 
 
 
(n=15) 
 
7 
8 
 
 
 
(n=13) 
2 
4 
7 
 
 
TLM = Transoral Laser Microsurgery, CRT = Chemoradiotherapy 
SD = Standard Deviation 
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Table 2. Pre – and 3-month post treatment swallowing scores for patients with both scores. 
Swallowing score TLM Mean (SD) [number=] 
(Median, Interquartile range) 
CRT Mean (SD) [number=] 
(Median, Interquartile range) 
Pre- MDADI 89.7 (11.7) [n=21] 
(93.7, 76.8-100) 
81.4 (17.2) [n=26] 
(76.8, 64.7-99.7) 
3 month MDADI 77.9 (14.4) [n=21] 
(77.9, 69.5-88.4) 
59.1 (17.1) [n=26] 
(57.9, 47.4-73.7) 
Pre- PSS 93.5 (16.6) [n=20] 
(100, 100-100) 
88.9 (21.8) [n=28] 
(100, 55-100) 
3 month PSS 85.0 (21.9) [n=20] 
(90, 85-100) 
41.8 (32.8) [n=28] 
(40, 10-50) 
Pre- WST 18.5 (8.2) [n=21] 
(16.6, 10.8-25.0) 
16.8 (7.5) [n=28] 
(14.3, 11.1-22.5) 
3 month WST 17.9 (7.1) [n=21] 
(18.6, 12.2-25.0) 
11.4 (9.0) [n=28] 
(11.1, 2.0-19.2) 
 
TLM = Transoral Laser Microsurgery, CRT = Chemoradiotherapy 
MDADI = MD Anderson Dysphagia Inventory, PSS = Performance Status Scale Normalcy of Diet 
WST = Water Swallow Test 
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 Figure 1 Mean MD Anderson Dysphagia Inventory scores and 95% confidence intervals (error bars) 
for patients with observations at both baseline (pre-treatment) and 3 months 
 
 
TLM = Transoral Laser Microsurgery, CRT = Chemoradiotherapy 
MDADI = MD Anderson Dysphagia Inventory 
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 Figure 2 Mean Performance Status Scale - Normalcy of diet scores and 95% confidence intervals 
(error bars) for patients with observations at both baseline (pre-treatment) and 3 months 
 
 
 
TLM = Transoral Laser Microsurgery, CRT = Chemoradiotherapy 
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 Figure 3 Mean swallow capacity (Water Swallow Test) scores and 95% confidence intervals (error 
bars) for patients with observations at both baseline (pre-treatment) and 3 months 
 
 
 
  
TLM = Transoral Laser Microsurgery, CRT = Chemoradiotherapy 
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